Eisai Inc. — China drug registrations and re-registration deadlines
3 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-09-10. Earliest re-registration deadline: 2028-07-04.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字SJ20240001 | Leqembi 仑卡奈单抗注射液 | 2029-01-04 | 2028-07-04 |
| 国药准字SJ20240002 | Leqembi 仑卡奈单抗注射液 | 2029-01-04 | 2028-07-04 |
| 国药准字SJ20260041 | Lecanemab Injection (Subcutaneous Injection) 仑卡奈单抗注射液（皮下注射） | 2031-09-01 | 2031-03-01 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-09-10, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.